Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
CAMBRIDGE, Mass., May 08, 2018 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a fireside chat at the Bank of America Merrill Lynch 2018 Health Care Conference on Tuesday, May 15, 2018, at 8 a.m. PT (11:00 a.m. ET) in Las Vegas, Nevada.
A live webcast of the presentation will be available on the Investors & Media section of the Editas Medicine website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the presentation.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Contacts
Media:
Cristi Barnett
(617) 401-0113
[email protected]
Investors:
Mark Mullikin
(617) 401-9083
[email protected]
